FDA 批准首个经导管三尖瓣置换系统 Evoque，用于治疗有严重症状的三尖瓣反流患者。 FDA approves first transcatheter tricuspid valve replacement system, Evoque, for severe symptomatic tricuspid regurgitation patients.
FDA 已批准首个经导管三尖瓣置换系统，称为 Evoque 三尖瓣置换系统。 The FDA has approved the first transcatheter tricuspid valve replacement system, called the Evoque tricuspid valve replacement system. 该系统旨在治疗尽管接受了最佳药物治疗但仍有严重症状的三尖瓣反流的患者。 This system is designed to treat patients with severe symptomatic tricuspid regurgitation despite optimal medical therapy. Evoque 系统于 2023 年 10 月获得欧盟批准，代表了三尖瓣反流治疗的重大进步，为高风险外科手术提供了替代方案。 The Evoque system was approved by the EU in October 2023 and represents a significant advancement in the treatment of tricuspid regurgitation, offering an alternative to high-risk surgical procedures.